ClinicalTrials.gg
CompletedNCT03375515Updated Mar 8, 2021

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

A Phase 3 interventional study of Hydromorphone and PCA pump in Cancer Pain, sponsored by Fujian Cancer Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-03-08.

Sponsored by Fujian Cancer Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies in Cancer Pain with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Cancer Pain · China.

Enrollment
4th of 24
214 · median 110
Started
2018
with 2 others
Phase 3
5 of 31
1 open now
Registered
6th of 31
by date
Lead sponsor
3 of 31
Fujian Cancer Hospital

Among the 31 studies in Cancer Pain with a site in China, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2018, is one of 5 in phase 3, and was the 6th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

13 of the 31 studies in Cancer Pain with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cancer Pain with a site in China, or all of them as a file.
02

Study summary

A large number of studies have shown that patients feel more satisfied with hydromorphone in the pain management. and a systematic review found that hydromorphone may be better suited than morphine for titration of acute analgesia. However, current researches on intravenous opioid titration for cancer pain such as hydromorphone are relatively insufficient in China. Therefore, a prospective, multi-center, randomized controlled study is conducted to assess the efficacy and safety of comparing patient-controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain.

Read the detailed description

The opioid dose for individual with cancer pain to provide adequate relief of pain with an acceptable degree of side effects is variable. Opioid titration is a process to obtain the tailored dose. Conventional titration is administered by a clinician or nurse. PCA is that patients control cancer pain by self-administration of intravenous opioids using programmable pump. The aim of our study is to evaluate the efficacy of PCA titration versus conventional titration intravenously for severe cancer pain (10-point numerical rating scale, NRS ≥ 7). Injectable Hydromorphone was selected as pharmaceutical analgesics, which works as well as morphine and oxycodone and had similar side effects.

03

Conditions studied

  • Cancer Pain

Browse trials for

Keywords

  • hydromorphone titration
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With written signed voluntarily by patients themselves.
  2. Cancer patients aged 18-70 years old.
  3. Patients with cancer pain more than or equal to NRS 7 during previous 24 hours.
  4. Patients who will not be treated with radiotherapy within 7 days prior to randomization and during study.
  5. Patients who need chemotherapy, long term administration of hormone, targeted therapy, or bisphosphonates therapy should undergo a stable anti- tumor therapy prior to randomization.
  6. Patients or his/her caregivers who are able to fill out the questionnaire forms.
  7. Ability to correctly understand and cooperate with medication guidance of doctors and nurses.
  8. Without a history of anaphylaxis of narcotic drugs.
  9. Without psychiatric problems.
  10. performance status ≤3.
  11. Not participated in another drug clinical trial within one month before inclusion(including hydromorphone).

Exclusion criteria

Exclusion Criteria:

  1. Patients diagnosed with non-cancer pain or unexplained pain.
  2. Patients suffered with post-op pain.
  3. Patients having paralytic ileus.
  4. Patients who have to hydromorphone.
  5. There are abnormal lab results, with obvious clinical significance, such as the creatinine ≥ 2 fold of value, or or AST ≥ 2.5 fold of upper limit of normal value (≥ 5 fold,to the patients with liver or primary liver cancer), or liver function of Child C grade.
  6. Patients having a incoercible Nausea and vomiting.
  7. Monoamine oxidase inhibitor (MAOI) was administrated two week before randomization.
  8. Patients who are pregnant or lactating,who plans to be pregnant within one month after the trial(including male).
  9. Patients who are opioid abuse.
  10. Patients who are alcohol abuse.
  11. Patients who are cognitive dysfunction.
  12. Patients having a severe psychotic depression.
  13. Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unable to participate in a clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    PCA IV Hydromorphone titration

    PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.

    Drug: Hydromorphone · Device: PCA pump

  • Active comparator
    non-PCA IV Hydromorphone titration

    Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.

    Drug: Hydromorphone

Interventions

  • 1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes. 2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.

  • DevicePCA pump

    1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone. 2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs.

06

What researchers measure

Primary outcomes

  1. The time of successful titration in 24 hours

    The satisfied pain control was defined NRS pain score ≤ 3 at rest in at least 2 consecutive assessment (15 minutes interval). The time needed to successful titration was extended to achieve satisfied pain control again if NRS pain score ≥ 7 after satisfied pain control within 24 hours. The failure of successful titration was defined that satisfied pain control does not achieve within 24 hours.

    Time frame: In 24 hours

Secondary outcomes

  1. The percentage of patients titrated successfully within 60 minutes

    The percentage of patients who titrated successfully within 60 minutes

    Time frame: Up to 60 minutes

  2. The percentage of patients titrated successfully within 24 hours

    The percentage of patients who titrated successfully within 24 hours

    Time frame: Up to 24 hours

  3. The mean NRS pain score of 24 hours

    The Numerical Rating Scale (NRS) is used to assess the severity of pain. The scale represents pain levels in 0-10 numbers, with 0 indicating no pain and 10 indicating the most severe pain. Ask the patient to choose the number that best represents his or her pain level, or ask the patient to ask: How severe is participant's pain? The health care provider selects the appropriate number based on the patient's description of the pain. 1-3 points indicate mild pain, 4-6 points indicate moderate pain, and 7-10 points indicate severe pain. "The mean NRS pain score of 24 hrs" is defined as the sum of the scores within 24 hours divided by the number of evaluations within 24 hours.

    Time frame: Up to 24 hours

  4. The total dose of hydromorphone titrated from start of titration to TST

    The total dose of hydromorphone titrated from start of titration to TST

    Time frame: Up to 24 hours

  5. The total dose of hydromorphone titrated within 24 hrs

    The total dose of hydromorphone titrated within 24 hrs

    Time frame: Up to 24 hours

  6. Improvement of patient symptoms

    The change from baseline in questionnaire: Chinese version of the Edmonton Symptom Assessment System

    Time frame: Up to 24 hours

  7. Adverse Events

    treatment-related Adverse Events:

    Time frame: Up to 7 days

07

Study locations

1 site
  • Rongbo Lin
    Fuzhou, Fujian 350014, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Dec 2019, 14 months.

Of 15 phase 3 interventional studies under Cancer Pain, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 51. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 18, 2017
StartActual
Sep 29, 2018
Primary completionActual
Dec 10, 2019
CompletionActual
Jan 10, 2020
Last update
Mar 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03375515
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Sep 29, 2018
Primary completion
Dec 10, 2019
Completion
Jan 10, 2020
Last update
Mar 8, 2021

Study contacts

Rongbo Lin
study director · Fujian Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion